High resolution profiling of cellular communities in the tumor microenvironment - PROJECT SUMMARY/ABSTRACT
The tumor microenvironment (TME) is comprised of diverse immune and stromal elements – each with
context-dependent phenotypic states and distinct functions – that interact with cancer cells to form unique cellular
communities. In recent years, major advances have been made in understanding the cross-talk between tumor
and TME cell populations in shaping metastasis, and in leveraging it for therapies. However, a pan-cancer
characterization of single-cell communities within the TME, both in primary and metastatic tumor deposits, is
currently lacking. Moreover, circulating cell-free nucleic acids in peripheral blood plasma have emerged as
promising biomarkers for noninvasive detection of cancer, and for issue-of-origin mapping. However, no liquid
biopsy assays have been developed to monitor the cell states and cellular communities of the TME.
I hypothesize that large-scale profiling of TME communities could present new therapeutic
opportunities to transform cancer treatment. To study TME communities at scale, I recently developed
EcoTyper, a new machine learning framework for delineating cell states and multicellular communities, termed
ecotypes, from bulk tumor expression data. Using EcoTyper, I constructed the first global atlas of
transcriptionally-defined cell states and ecotypes in >6,000 primary bulk tumor samples from 16 types of
carcinoma and >1,000 diffuse large B cell lymphomas. Although these atlases are major milestones toward
understanding the TME, they do not achieve single-cell resolution. While efforts to construct pan-cancer single-
cell atlases have been described, they do not identify multicellular communities, nor do they provide automated
methods to discover new cell states or interrogate them in new data.
I propose that large-scale ecotype profiling (1) can be performed at single-cell resolution via
dedicated improvements to the EcoTyper platform, (2) can delineate the determinants of progression
to metastatic disease, (3) and can be used to noninvasively monitor clinically relevant heterogeneity in
the TME from liquid biopsies. In the K99 phase, I will significantly improve upon EcoTyper by extending it to
identify cell states and ecotypes from the joint analysis of large collections of single-cell RNA sequencing
(scRNA-seq) data. I will also define a global single-cell atlas of cell states that extends our previously published
pan-carcinoma atlas; and will derive a global atlas of ecotypes across multiple metastatic sites, including liver,
brain and lymph nodes, by analyzing thousands of metastatic carcinomas. In the R00 phase, my group will
develop bioinformatics tools for resolving epigenomic signatures of ecotypes, including methods that leverage
single-cell and bulk methylation data to define methylation signatures of TME ecotypes, and will leverage them
to test whether tumor ecotypes can be reliably detected from circulating nucleic acid molecules.